Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1514-1525

  Crisp, Jessica L ^a   Savariar, Elamprakash N ^a   Glasgow, Heather L ^a,b   Ellies, Lesley G ^b   Whitney, Michael A ^a   Tsien, Roger Y ^a,b,c  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLOPEPTIDE; GELATINASE B; MATRIX METALLOPROTEINASE; MONOMETHYLLAURISTATIN E; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CONTRAST MEDIUM; GELATINASE A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLUORESCENCE IMAGING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; MATRIX METALLOPROTEINASE 2; MICE; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY;

EID: 84902655584     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1067     Document Type: Article

References (32)

1. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004;101:17867-72. (Pubitemid 40051978)
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70. (Pubitemid 27371946)
3. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39. (Pubitemid 43292566)
4. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-5. (Pubitemid 37363416)
5. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010;107:4317-22.
6. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al.In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol 2009;1:382-93.
7. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010;107:4311-6.
8. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-93. (Pubitemid 26181048)
9. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
10. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100. (Pubitemid 37328796)
11. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90. (Pubitemid 37328795)
12. Jiao Y, Feng X, Zhan Y, Wang R, Zheng S, Liu W, et al. Matrix metalloproteinase-2 promotes alphavbeta3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS ONE 2012;7:e41591.
13. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2in breast carcinoma cells. Exp Cell Res 2001;263:209-23. (Pubitemid 32989095)
14. Puyraimond A, Fridman R, Lemesle M, Arbeille B, Menashi S. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 2001;262:28-36. (Pubitemid 32989005)
15. Mebrahtu E, Zheleznyak A, Hur MA, Laforest R, Lapi SE. Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity. Nucl Med Biol 2013;40:190-6.
16. Zhu L, Xie J, Swierczewska M, Zhang F, Lin X, Fang X, et al. Dual-functional, receptor-targeted fluorogenic probe for in vivo imaging of extracellular protease expressions. Bioconjug Chem 2011;22:1001-5.
17. Pettit GR. The dolastatins. Fortschr Chem Org Naturst 1997;70:1-79.
18. Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FW, Pettit GR, et al. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model. Int J Oncol 1999;15:367-72.
19. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
20. Okeley NM, Alley SC, Senter PD. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol Oncol Clin North Am 2014;28:13-25.
21. Savariar EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P, et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res 2013;73:855-64.
22. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65. (Pubitemid 36988057)
23. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
24. Gibby K, You WK, Kadoya K, Helgadottir H, Young LJ, Ellies LG, et al. Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Breast Cancer Res 2012;14:R67.
25. Miotti S, Bagnoli M, Ottone F, Tomassetti A, Colnaghi MI, Canevari S. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65:479-91. (Pubitemid 27240914)
26. Dubowchik GM, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 1998;8:3341-6. (Pubitemid 28547069)
27. Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 1999;44:395-402. (Pubitemid 29455585)
28. Bajjuri KM, Liu Y, Liu C, Sinha SC. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem 2011;6:54-9.
29. Vartak DG, Lee BS, Gemeinhart RA. In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2. Mol Pharm 2009;6:1856-67.
30. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 2010;32:35-48.
31. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression pro filing predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
32. Liu Y, Bajjuri KM, Liu C, Sinha SC. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug. Mol Pharm 2012;9:168-75.